STERIS(STE) - 2025 Q1 - Quarterly Report

Financial Performance - Revenues increased by 8.1% to $1,279.5 million for the three months ended June 30, 2024, compared to$1,183.4 million for the same period in the prior year[86]. - Gross profit percentage remained stable at 44.7% for both the first three months of fiscal 2025 and fiscal 2024[86]. - Income from operations decreased to $185.5 million in the first three months of fiscal 2025 from$197.8 million in the same period of fiscal 2024, primarily due to restructuring expenses[86]. - Cash flows from operations were $303.7 million for the first three months of fiscal 2025, an increase from$281.1 million in the same period of fiscal 2024[86]. - Free cash flow for the first three months of fiscal 2025 was $195.7 million, down from$214.5 million in the same period of fiscal 2024[86]. - Total revenues increased by 8.1% to $1,279.5 million for the three months ended June 30, 2024, compared to$1,183.4 million for the same period in the prior year[90]. - Gross profit for the three months ended June 30, 2024, was $572.4 million, an increase of 8.2$529.0 million in the prior year, with a gross profit percentage of 44.7%[91]. - Operating expenses increased by 16.8% to $386.9 million, driven by a 9.5$335.6 million[92]. - Total segment operating income increased by 7.4% to $285.4 million for the three months ended June 30, 2024, compared to$265.7 million in 2023[101]. - Net income for the three months ended June 30, 2024, was $107.3 million, reflecting strong operational performance[106]. Debt and Cash Management - The debt-to-total capital ratio improved to 26.7$231.3 million as of June 30, 2024[103]. - The company intends to use existing cash and cash equivalents for both short-term and long-term capital expenditures, depending on various uncertain factors[103]. Acquisitions and Divestitures - The company completed the acquisition of surgical instrumentation assets from Becton, Dickinson and Company for $539.8 million, which was financed through existing credit facilities[85]. - The company recorded net proceeds of$41.5 million from the sale of its Controlled Environment Certification Services business, with a pre-tax gain of $18.8 million[85]. - The Dental segment was sold for total cash consideration of$787.5 million, with an additional contingent payment of up to $12.5 million based on revenue targets[86]. - The company received proceeds of$809.6 million from the sale of its Dental segment and CECS business during the first three months of fiscal 2025[102]. Segment Performance - Service revenues rose by 9.2% to $623.2 million, while consumable revenues increased by 20.8$414.1 million, reflecting growth in the Healthcare and Life Sciences segments[90]. - Healthcare segment revenues increased by 10.1% to $901.2 million for the three months ended June 30, 2024, compared to$818.9 million for the same period in 2023[98]. - AST segment revenues rose by 7.2% to $249.8 million for the three months ended June 30, 2024, compared to$233.1 million in the prior year[98]. - Life Sciences segment revenues decreased by 2.2% to $128.5 million for the three months ended June 30, 2024, down from$131.4 million in the same prior year period[98]. - The Healthcare segment's backlog decreased to $362.0 million as of June 30, 2024, from$491.7 million a year earlier[98]. - The Life Sciences backlog also decreased to $72.2 million as of June 30, 2024, down from$104.9 million in the prior year[98]. Expenses and Taxation - Research and development expenses grew by 3.6% to $25.6 million, focusing on new product development and technological innovations[92]. - The company recorded total pre-tax restructuring expenses of$28.1 million for the three months ended June 30, 2024, related to a targeted restructuring plan[93]. - Interest expense decreased by $2.0 million to$30.4 million, primarily due to a lower principal amount of debt outstanding[94]. - Income tax expense for the three months ended June 30, 2024, was $35.3 million, with an effective income tax rate of 20.1$25.0 million per year from the restructuring actions, with benefits expected to materialize in fiscal 2026 and beyond[92]. - STERIS's restructuring plan may not yield expected benefits or be realized on the anticipated timeline, affecting financial results[112]. - The company faces potential risks from public health crises impacting operations, supply chain, and costs[112]. - STERIS's ability to integrate acquired businesses successfully is uncertain, which could lead to increased costs or liabilities[112]. - The company is monitoring the impact of international unrest and economic downturns on demand for its products and services[112]. Legal and Regulatory Matters - The company is involved in various legal proceedings and claims, but does not anticipate a material adverse effect on its financial position or results of operations[110]. - STERIS's quarterly report includes forward-looking statements that may be affected by various factors, including market conditions and regulatory actions[111]. Market Risks - The company is subject to various market risks, including interest rate, currency, and commodity risks, which have not changed materially since March 31, 2024[114]. - STERIS's financial results could be impacted by the availability and price changes of basic raw materials, with long-term supply contracts in place to ensure reliability[114]. - The company has commodity swap contracts to buy 591.8 thousand pounds of nickel, which may help hedge against price fluctuations[114]. - There were no changes in internal control over financial reporting that materially affected the company's reporting during the quarter ended June 30, 2024[115].